Search Results

240 results for java

Why Is Cassava Sciences (SAVA) Stock Up 15% Today?

By Josh Enomoto, InvestorPlace Contributor

Although Cassava Sciences’ issuance of warrants presents risks, the underlying Phase 3 trial support boosted SAVA stock.

Cassava Sciences Has Value and Is Likely To Proceed to Phase 3

By Mark R. Hake, CFA

SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or…

Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data

By Louis Navellier and the InvestorPlace Research Staff

As Cassava Sciences made progress in treating Alzheimer’s, SAVA stock is on a powerful path to significantly higher prices.

2 Signals to Watch Before Buying SAVA Stock

By Louis Navellier and the InvestorPlace Research Staff

SAVA stock has a ways to go before it’s a buying opportunity again, but given the chance recent excessive optimism morphs back into excessive pessimism,…

3 Restaurant Stocks to Flee Before They Fall

By Ian Bezek, InvestorPlace Contributor

Between inflation, a weakening economy, and falling consumer spending power, here are the restaurant stocks to sell.

SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.

By Samuel O'Brient, InvestorPlace Reporter

The CEO of Cassava Sciences is stepping down, effective immediately. Here’s what this means for troubled SAVA stock.

Risk-on Biotech Investors Should Buy Cassava Sciences

By Alex Sirois, InvestorPlace Contributor

SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer’s drug nearing launch.

Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near

By Louis Navellier and the InvestorPlace Research Staff

SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam.

Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer’s Results

By Mark R. Hake, CFA

Cassava Sciences stock could jump with its upcoming Alzheimer’s results. SAVA stock options show the lofty expectations investors have.

Cassava Sciences News: Why Is SAVA Stock Trending Today?

By William White, InvestorPlace Writer

Cassava Sciences stock is down on Tuesday even as investors take note of SAVA shares alongside a couple of pieces of news.

Feast on Profits: 3 Fast Food Stocks Cooking Up Hot Gains

By Joey Frenette, InvestorPlace Contributor

Fast food stocks have intriguing plans that could help them gain market share over the coming year and beyond.

3 Growth Stocks to Set Your Portfolio Up for Success in 2024

By Marc Guberti, InvestorPlace Contributor

Are you looking for promising growth stock ideas? Consider these top stocks that can shine in 2024 and beyond.

Whole Foods Market, Inc. (WFM) Stock Only Has Upside in a Sale

By Marie Brodbeck, InvestorPlace Contributor

The only upside for Whole Foods (WFM) is if the company goes up for sale, and that possibility is responsible for WFM stock’s recent jump.

3 Low-Priced Stocks Poised for a 30% Breakout

By Joel Baglole, InvestorPlace Contributor

Investors should act quick and buy-the-dip in these low-priced breakout stocks while they are on sale and before they inevitably rise.

3 Must-Watch Stocks as IPO Valuations Skyrocket

By Chris MacDonald, InvestorPlace Contributor

The IPO market has come back to life, leading to outsized investor interest in these must-watch stocks in recent weeks.

Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results

By Shrey Dua, InvestorPlace Senior Financial News Reporter

Cassava Sciences (SAVA) stock is down 11% on underwhelming results from its clinical trials for its Alzheimer’s treatment.

CAVA Stock Earnings: Cava Group Beats EPS, Beats Revenue for Q2 2024

By InvestorPlace Earnings

CAVA stock results show that Cava Group beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

CAVA Stock Earnings: Cava Group Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings

CAVA stock results show that Cava Group beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today

By Samuel O'Brient, InvestorPlace Reporter

Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.

3 New Stocks Set to Explode Higher

By Joel Baglole, InvestorPlace Contributor

Investors can feel good taking a gamble on each of these new stocks to buy that are all set up for long-term success.

Caution! It’s Not Safe to Jump on the SAVA Stock Hype Train.

By Louis Navellier and the InvestorPlace Research Staff

Rumors and speculation surrounding Cassava Sciences incited a buying frenzy in SAVA stock, but this isn’t the time to jump on the hype train.

3 Plunging Restaurant Stocks to Eat Up for Cheap

By Joey Frenette, InvestorPlace Contributor

The quick-serve restaurant industry has been rather turbulent in recent quarters. They may be top restaurant stocks for year’s end.

Wall Street Favorites: 3 Restaurant Stocks With Strong Buy Ratings for June 2024 

By Joey Frenette, InvestorPlace Contributor

Restaurant stocks can be a delicious pick-up this summer for investors seeking growth and fairly reasonable multiples.

3 Promising Stocks to Buy With 50% Upside Potential

By Joel Baglole, InvestorPlace Contributor

Consider buying these growth stocks as a means of boosting a portfolio and growing profits at a rapid rate, now and in the future.

8 – 10 of 240 results